Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MRNA doses 12x-50x the vaccine dose CVAC requires - will be a Competitive advantage for $CVAC in terms of dose output. “mRNA-1273
Participants will receive 1 intramuscular (IM) injection of 100 microgram (ug) mRNA-1273 on Day 1 and on Day 29.”
“What makes CureVac different from the rivals in this race is dosage. The biotech is testing single-digit micrograms — 2, 4, 6 and 8 — in Phase I. And Haas says that the added potency of their vaccine should make it effective at extremely low dosing, something that would allow them to go further without scaling up like the high-dosage vaccines that are in development now.
CVAC has a GMP3 facility producing vaccine at risk. And Haas says they plan to add a group of additional GMP3 facilities in Q2 of next year, likely clustered together, which can produce hundreds of millions of doses for delivery in 2021, as they boot up a new GMP4 facility to handle the large production quantities for future use of their mRNA products — which extend into a variety of areas, including oncology.”
CVAC CEO (contd Endpoints article) “Haas says he expects CureVac will be ready to read out the Phase I data on its coronavirus vaccine around September or October. And they’ll quickly vault into a new study for the elderly as well as the big pivotal study with 20,000 to 30,000 subjects, ramping up enrollment by the end of this year. That will set up a near-term strategy to get up and operating with commercial supplies in a matter of months.“
CVAC ”CEO Franz-Werner Haas outlined plans to start a pivotal study before the end of this year, with a timeline that puts them in play for an emergency use authorization in Q1 of next year. And they are working out delivery deals now.”
https://endpts.com/3-weeks-3-big-investments-capped-by-a-213m-ipo-bring-curevacs-instant-cash-raise-to-a-cool-billion-dollars/
CVAC
“CureVac’s vaccines — which have never made it to approval but have some trial data backing them — can be made in 1 microgram doses, they can be made much faster than, say, Moderna’s vaccines. Hoerr says they could build millions of doses by summer, when they hope to start trials, and over a billion in a year or year and half.”
All MRNA Caccines are Not the same.
https://endpts.com/curevacs-ingmar-hoerr-tells-us-why-he-returned-to-take-on-a-pandemic-ngm-loses-a-president/
TSLA -CVAC https://www.fiercepharma.com/manufacturing/curevac-teaming-up-tesla-to-make-rna-microfactories-for-covid-19-shot
(H/T Mick-thanks)
CVAC happy to have a foothold on this best of Class (US Govt tried to buy- Germany, Bill Gates, and $GSK have stakes) Vaccine maker to the EU and world - when news out this PM of Big Pharma distribution negotiations 75 on Monday seems realistic.
$CVAC WORKING WIT TSLA
RE;
What To Know About The CureVac IPO
3:46 pm ET August 14, 2020 (Benzinga) Print
German biotech firm CureVac (NASDAQ: CVAC) opened for trading on Friday.
CureVac listed on the Nasdaq under the symbol CVAC. The company’s shares opened for trade at $40 and the IPO was priced at $16 per share
The Financials: CureVac is developing an mRNA vaccine for SARS-CoV-2 and has so far raised $213 million by offering 13.3 million shares at $16. The company has raised an additional $118 million in a concurrent private placement to insider Dietmar Hopp.
BofA Securities, Jefferies, Credit Suisse, Berenberg and Kempen acted as lead managers on the deal.
The Bill & Melinda Gates Foundation invested $40 million in the company in 2015.
Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.
The Company: CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 17 years' expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.
The company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies.
"CureVac also has another big name in its roster of partners: the firm is working on technology with Elon Musk's electric car giant Tesla," according to CNN Business. "The company has had a development and intellectual property agreement with Tesla since November 2015."
© 2020 http://www.Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
$CVAC Bid: 54.35 Ask: 54.65 Last: 54.57 Chg ($): 52.47 Vol:
$CVAC 50.05 +34.05 +212.81% USD 3:16PM EDT 18.240M
... CUREVAC IPO DAY ... $CVAC
MR. MENICHELLA: Thank you, Mr. President, Mr. Vice President. Thanks for having me here. I’m Dan Menichella, CEO of CureVac. We’re a clinical stage biotech company. We use messenger RNA technology, optimize the messenger RNA molecules. Once injected into the body, they instruct the cells on how to make proteins. For instance, we can use the mRNA technology to trigger an immune response against viruses, or we can get the body to increase its production of T-cells for cancer vaccines.
In this way, CureVac can make potent prophylactic vaccines and cancer treatments. The technology also works well to replace missing proteins so we can also work in (inaudible).
One strength of our technology is that we can produce prophylactic vaccines using a very low dose. So, for instance, the phase one rabies trial that we just completed was done at a one-microgram dose, so, in other words, a millionth of a gram dose — a very, very tiny dose.
And so, more broadly, our company focuses — so, this year, we have four programs in phase one clinical trials, and the coronavirus program would be the fifth program in phase one. We expect that the phase one program for coronavirus will start at the beginning of June.
Our technology platform is fast and it’s agile. We were the first messenger RNA company to have GMP manufacturing. We started in 2006. Currently, we have three large-scale GMP facilities, and we are up and running now. Today we have a fourth facility built, and we’re looking for additional capex to put the machinery in there. Once we have that machinery in the fourth building, we can make HUNDREDS OF MILLIONS of doses of the coronavirus vaccine. So we’re very excited about that and we want to help there.
Additionally, we have developed a fully automated production machine. This automated machine if part of the collaboration with CEPI. And additionally, with CEPI, we are working on the coronavirus. They have funded our efforts to get the program and the vaccine to phase one by June.
The key point here being that we believe we can develop the vaccine for COVID-19 very, very quickly, and we have the wherewithal to manufacture it, although we would like some additional help on our largest GMP fourth facility.
Again, we appreciate the opportunity to be here today, and thank you very much.
THE PRESIDENT: Thank you. Thank you very much. Appreciate it. - https://www.whitehouse.gov/briefings-statements/remarks-president-trump-members-coronavirus-task-force-meeting-pharmaceutical-companies/" rel="nofollow" target="_blank" >SOURCE: WHITEHOUSE.GOV
Bit too high right now....
May come down a bit... IMO
Why did they price it so low?
GLTA
$CAVC NICE FUNDING TO START WIT
RE;
CureVac in talks with pharma companies about partnership - Sueddeutsche
August 14, 2020, 12:28 pm
FRANKFURT, Aug 14 (Reuters) - German biotechnology firm CureVac is in talks with large drugmakers about a partnership to help market and distribute its prospective vaccine against the COVID-19 virus, its chief executive told Sueddeutsche Zeitung.
CureVac, backed by Microsoft founder and billionaire Bill Gates, listed on the Nasdaq stock market on Friday, raising $213 million.
$CVAC GOOD SHOOTING
RE;
got in below $40 today ... $CVAC
CureVac in talks with pharma companies about partnership - Sueddeutsche
August 14, 2020, 12:28 pm
FRANKFURT, Aug 14 (Reuters) - German biotechnology firm CureVac is in talks with large drugmakers about a partnership to help market and distribute its prospective vaccine against the COVID-19 virus, its chief executive told Sueddeutsche Zeitung.
CureVac, backed by Microsoft founder and billionaire Bill Gates, listed on the Nasdaq stock market on Friday, raising $213 million.
CureVac's stock debuts at nearly triple the IPO price
$CAVC GOOD ONE MAYBE $100 COMING
RE;
CVAC
- german Vaccine maker -US Government t tried to buy - I just initiated -
like getting $NVAX in the 40s.
... we got in below $40 today ... $CVAC
$CVAC 48.60 +32.60 +203.75% USD 1:46PM EDT -
HI DARE CONGRATS
CVAC
- german Vaccine maker -US Government t tried to buy - I just initiated -
like getting $NVAX in the 40s.
... we got some $CVAC shares today ...
$CVAC
MarketWatch • 4 hours ago
CureVac raises $213.3 million in IPO after pricing at $16 a share, high end of proposed range
CVAC—(mRNA company)—IPOs 15.33M* shares @$16.00:
https://www.curevac.com/news/curevac-announces-pricing-of-initial-public-offering
Followers
|
11
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
180
|
Created
|
08/14/20
|
Type
|
Free
|
Moderators |
PARTNER
PARTNER
PARTNER
Respirational syncytial virus
PARTNER
DETAILS ON OTHER INFECTIOUS DISEASES
Rota, malaria, universal influenza
PARTNER
DETAILS ON VARIOUS PROJECTS
always like to check for a history of revenue growth. You can too, by accessing this free chart of historic revenue and earnings in this detailed graph.
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
https://finviz.com/quote.ashx?t=cvac&ty=c&ta=1&p=d
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments.
There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least.
Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Insider ownership is positive when it signals leadership are thinking like the true owners of the company.
However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
We can see that insiders own shares in CureVac N.V.. It is a very large company, and board members collectively own US$1.1b worth of shares (at current prices).
It is good to see this level of investment. You can check here to see if those insiders have been buying recently.
With a 21% ownership, the general public have some degree of sway over CureVac. While this group can't necessarily call the shots,
it can certainly have a real influence on how the company is run.
CureVac has entered into a collaboration with Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company,
to access the full suite of Arcturus’ lipid-mediated delivery intellectual property to enable the development of mRNA product candidates.
TÜBINGEN, Germany/ BOSTON, USA – August 14, 2020 – CureVac B.V. (“CureVac” or the “Company”), a clinical-stage biopharmaceutical company
developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the pricing of its
initial public offering of 13,333,333 common shares at an initial public offering price of $16.00 per common share, for total gross proceeds of approximately $213.3 million.
In addition, the Company has granted the underwriters a 30-day option to purchase up to an
additional 1,999,999 common shares at the public offering price, less underwriting discounts and commissions. All of the common shares are being offered by CureVac.
The shares are scheduled to begin trading on the Nasdaq Global Market today, August 14, 2020, under the ticker symbol “CVAC.”
The offering is expected to close on August 18, 2020, subject to customary closing conditions.
BofA Securities, Jefferies and Credit Suisse are acting as joint book-running managers for the proposed offering, with Berenberg and Kempen & Co acting as passive book-running managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (“SEC”) on August 13, 2020.
The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available,
for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the final prospectus, when available, may be obtained from
BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001,
by telephone at (800) 299-1322 or by email at dg.prospectus_requests@bofa.com; Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com;
and Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, North Carolina 27560, by telephone at (800) 221-1037 or by email at usa.prospectus@credit-suisse.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About CureVac
CureVac is a global clinical-stage biopharmaceutical company in the field of messenger RNA (mRNA) technology with expertise in developing
and optimizing this versatile molecule for medical purposes.
The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.
The company applies its technologies for the development of prophylactic vaccines, cancer therapies,
antibody therapies and the treatment of protein therapies. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.
CureVac Investor Relation Contact
Dr. Sarah Fakih, Vice President Investor Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
sarah.fakih@curevac.com
CureVac Media Contact
Thorsten Schüller, Director Corporate Communications
CureVac, Tübingen, Germany
T: +49 7071 9883-1577
thorsten.schueller@curevac.com
sarah.fakih@curevac.com
*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |